佛羅里達 的 慢性淋巴性白血病 臨床試驗
34 項針對 慢性淋巴性白血病 的研究正在 佛羅里達 各地點尋找參與者。
佛羅里達 的城市
- Jacksonville11 項研究
- Miami9 項研究
- Tampa8 項研究
- Sarasota5 項研究
- St. Petersburg4 項研究
- Cape Coral4 項研究
- Miami Beach4 項研究
- West Palm Beach3 項研究
- Kendall3 項研究
官方研究文本（英文）
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
- UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables
- UM Sylvester Comprehensive Cancer Center at Coral Springs, Coral Springs
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach, Deerfield Beach
- 還有 9 項
招募中3 期
65 歲及以上 · 所有性別 · 更新於 2026年10月2日 · NCT07321652Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Mount Sinai Comprehensive Cancer Center at Aventura, Aventura
- Schulze Family Foundation Cancer Clinic - Bonita Health Center, Bonita Springs
- Morton Plant Hospital, Clearwater
- 還有 11 項
招募中觀察性研究歡迎健康志工
40 至 75 歲 · 所有性別 · 更新於 2026年10月2日 · NCT05334069A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
- Study Site 102, St. Petersburg
招募中3 期
18 歲及以上 · 所有性別 · 更新於 2026年10月1日 · NCT07582432Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- Holy Cross Hospital, Fort Lauderdale
招募中3 期
18 歲及以上 · 所有性別 · 更新於 2026年9月30日 · NCT04269902A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
- GC2202 Study Site 103, St. Petersburg
招募中3 期
18 歲及以上 · 所有性別 · 更新於 2026年9月30日 · NCT05645107A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
- Cleveland Clinic Florida, Weston
招募中3 期
18 歲及以上 · 所有性別 · 更新於 2026年9月28日 · NCT06943872A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Mayo Clinic Jacksonville, Jacksonville
- Mount Sinai Medical Center Braman Comprehensive Cancer Center, Miami
- Tampa General Hospital Cancer Institute, Tampa
招募中1/2 期
18 歲及以上 · 所有性別 · 更新於 2026年9月28日 · NCT05006716A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
- Mayo Clinic Jacksonville, Jacksonville
- Mount Sinai Medical Center Braman Comprehensive Cancer Center, Miami
- Moffitt Cancer Center, Tampa
招募中3 期
18 歲及以上 · 所有性別 · 更新於 2026年9月28日 · NCT07277231A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
- Florida Oncology and Hematology, Fort Myers
- Baptist Md Anderson Cancer Center, Jacksonville
- Cleveland Clinic Florida, Weston
招募中3 期
18 歲及以上 · 所有性別 · 更新於 2026年9月28日 · NCT06846671A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
- Moffitt Cancer Center, Tampa
招募中1/2 期
18 歲及以上 · 所有性別 · 更新於 2026年9月28日 · NCT06697184A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Mayo Clinic Jacksonville, Jacksonville
- Cancer Specialists of North Florida, Jacksonville
- Mount Sinai Medical Center Braman Comprehensive Cancer Center, Miami
招募中3 期
18 歲及以上 · 所有性別 · 更新於 2026年9月28日 · NCT06973187A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
- Clermont Oncology Center ( Site 5430), Clermont
- Memorial Hospital West ( Site 5410), Pembroke Pines
招募中3 期
18 歲及以上 · 所有性別 · 更新於 2026年9月24日 · NCT05947851A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
- Lynn Cancer Center at Boca Raton Regional Hospital ( Site 0063), Boca Raton
- Clermont Oncology Center ( Site 0046), Clermont
- Florida Cancer Specialists - South ( Site 7001), Fort Myers
- 還有 1 項
招募中3 期
18 歲及以上 · 所有性別 · 更新於 2026年9月24日 · NCT06136559A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Cancer Specialists, LLC, Jacksonville
招募中4 期
18 歲及以上 · 所有性別 · 更新於 2026年9月22日 · NCT07218341Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- SSAK Partners, Coral Springs
- Mayo Clinic - Jacksonville, Jacksonville
招募中3 期
18 歲及以上 · 所有性別 · 更新於 2026年9月21日 · NCT07648264A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
- University of Miami, Coral Gables
- Florida Cancer Specialists, Sarasota
招募中2 期
18 歲及以上 · 所有性別 · 更新於 2026年9月17日 · NCT07221500Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- H. Lee Moffitt Cancer Center, Tampa
招募中1 期
18 歲及以上 · 所有性別 · 更新於 2026年9月8日 · NCT03666000Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
- Mayo Clinic, Jacksonville
- Moffitt Cancer Center, Tampa
招募中1/2 期
12 歲及以上 · 所有性別 · 更新於 2026年9月3日 · NCT04588922Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
- University of Miami, Coral Gables
招募中1/2 期
18 歲及以上 · 所有性別 · 更新於 2026年8月28日 · NCT07520006A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Florida Cancer Specialists, Fort Myers
- Cancer Specialists of North Florida -St Augustine, Saint Augustine
- Florida Cancer Specialists East, West Palm Beach
招募中3 期
18 歲及以上 · 所有性別 · 更新於 2026年8月17日 · NCT05254743Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- Mayo Clinic, Clinical Trials Referral Office, Jacksonville
招募中1/2 期
13 至 90 歲 · 所有性別 · 更新於 2026年8月6日 · NCT06533579A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- University of Miami, Miami
- Florida Cancer Specialists, Sarasota
招募中1 期
18 歲及以上 · 所有性別 · 更新於 2026年7月2日 · NCT05131022A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
- Mt Sinai Comprehensive Cancer Center, Miami Beach
招募中2 期
18 歲及以上 · 所有性別 · 更新於 2026年6月12日 · NCT07271667A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- University of Miami Hospital and Clinics, Sylvester Cancer Center, Miami
招募中2 期
18 歲及以上 · 所有性別 · 更新於 2026年5月19日 · NCT06588478The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- ASCLEPES Research Centers, Weeki Wachee
招募中1/2 期
12 至 95 歲 · 所有性別 · 更新於 2026年4月15日 · NCT04329728A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
- Malcolm Randall V.A. Medical Center /ID# 267825, Gainesville
- Cancer Specialists of North Florida - Jacksonville - AC Skinner Parkway /ID# 266713, Jacksonville
- Mid Florida Hematology And Oncology Center /ID# 269159, Orange City
- 還有 1 項
招募中3 期
18 歲及以上 · 所有性別 · 更新於 2026年4月9日 · NCT06428019Predictors of Health-Related QOL in Adults With CLL or Small Lymphocytic Lymphoma
- Moffitt Cancer Center, Tampa
招募中觀察性研究
18 歲及以上 · 所有性別 · 更新於 2026年4月1日 · NCT07030400Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial
- University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami
招募中2 期
18 歲及以上 · 所有性別 · 更新於 2026年3月13日 · NCT07218510A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
- Sylvester Comprehensive Cancer Center, Miami
- Florida Cancer Specialists, Sarasota
招募中4 期
18 歲及以上 · 所有性別 · 更新於 2026年3月2日 · NCT06876662A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
- Cancer Specialists, LLC, Jacksonville
- Sylvester Comprehensive Cancer Center, Miami
- Florida Cancer Specialists, Sarasota
招募中4 期
18 歲及以上 · 所有性別 · 更新於 2026年3月2日 · NCT06876649Study of SGR-1505 in Mature B-Cell Neoplasms
- Napa Research, Pompano Beach
招募中1 期
18 歲及以上 · 所有性別 · 更新於 2026年2月13日 · NCT05544019B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies
- Mayo Clinic in Florida, Jacksonville
招募中1 期
18 歲及以上 · 所有性別 · 更新於 2026年2月13日 · NCT06191887AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
- Mount Sinai Comprehensive Cancer Center, Miami Beach
- Moffitt Cancer Center, Tampa
招募中1 期
18 歲及以上 · 所有性別 · 更新於 2025年12月10日 · NCT05602363A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
- Florida Cancer Specialists, Sarasota
招募中1 期
18 歲及以上 · 所有性別 · 更新於 2025年10月2日 · NCT05780034資料來源：ClinicalTrials.gov，擷取日期 2026年10月5日。各研究自行設定資格標準；由研究團隊決定參與者資格。